Tag: pertuzumab

Now positive topline results from a new study, the DESTINY-Breast11 phase 3 trial (NCT05113251), confirmed that trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca)**, followed by paclitaxel, trastuzumab and pertuzumab (THP), demonstrated a statistically significant and clinically meaningful improvement in pCR rate versus Standard-of-Care (SoC; dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting in patients with high-risk, locally advanced HER2-positive early-stage breast cancer.

Positive topline results from a planned interim analysis of the phase 3 DESTINY-Breast09 (NCT04784715) trial showed trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca)* in combination with pertuzumab (Perjeta®; Genentech/Roche) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to taxane, trastuzumab (Herceptin®; Genentech/Roche) and pertuzumab (THP) as a first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.

Positive top-line data from a recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors support the drug to advance into two Phase 2...

José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...

Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...

The I-SPY 2 TRIAL, a private-public partnership combining personalized medicine with a novel investigational design, is a neoadjuvant Phase II clinical trial screening agents in combination with...

Preclinical data for XMT-1522, a novel HER2-targeting therapy based on Mersana Therapeutics' Dolaflexin platform, the company's most advanced Fleximer® proprietary immunoconjugate technology, demonstrates significant anti-cancer activity...